MetAlert (OTC: MLRT), a pioneer in location-sensitive health monitoring devices and wearable technology products, developed GPS SmartSole(R), a medical monitoring device integrated into an orthotic insole, facilitating discreet tracking and remote monitoring of those living with Alzheimer’s, dementia and autism, who have a tendency to wander and become lost. “The SmartSole enables tracking by utilizing a 4G cellular network and … can be configured to send alerts via email or text whenever someone enters or exits specific areas, giving caregivers the utmost peace of mind. MetAlert has further enhanced the capabilities of SmartSole by adding Wi-Fi and Bluetooth capabilities, creating what it has named SmartSole plus(R). The revamped product’s use of Wi-Fi enables indoor tracking within large concrete structures, while Bluetooth facilitates connection to other wearable medical devices,” a recent article reads. “Still, the company is pushing the boundaries of innovation and is currently developing the next generation of its insole product named BioStride. According to MetAlert, BioStride will be designed to continuously collect health data that may help identify patterns before and during episodes and, utilizing an artificial intelligence-powered backend, analyze trends and send alerts in the event of a crisis. This way, MetAlert plans to expand its tracking and monitoring platform.”
To view the full article, visit https://ibn.fm/ddDHl
About MetAlert Inc.
MetAlert and its subsidiaries are engaged in designing, developing, manufacturing, distributing, selling and licensing products, services and intellectual property in the GPS/BLE wearable technology, personal location, wandering assistive technology, and health data collection and monitoring sectors. With over 20 years of experience and an extensive patent portfolio, MetAlert is a leading solution provider for consumers/patients afflicted with movement, cognitive and spatial awareness disorders. This market represents approximately 2.9% of the world’s population. The company offers global end-to-end hardware, software and connectivity solutions, in addition to developing two-way tracking technologies, which seamlessly integrate with consumer products, enterprise and government agency applications. Utilizing the latest in miniaturized, low power consumption GPS, cellular, RF, NFC, and BLE technologies, caregivers are enabled to track and monitor patients in real time. The company is known for its game-changing and award-winning patented GPS SmartSole(R) — think Dr. Scholl’s meets LoJack, the world’s first invisible wearable technology tracking device created for those at risk of wandering due to Alzheimer’s, dementia, autism, and traumatic brain injury. MetAlert’s subscription-based business model is built around technology innovation with intellectual property protection. The company has international distributors servicing customers around the globe with subscribers in over 40 countries. MetAlert is a U.S. military government contractor and has other customers that include public health authorities, municipalities, emergency and law enforcement, private schools, assisted living facilities, NGOs, small business enterprises, senior care homes and consumers. For more information, visit the company’s website at www.MetAlert.com.
NOTE TO INVESTORS: The latest news and updates relating to MLRT are available in the company’s newsroom at https://ibn.fm/MLRT
About BioMedWire
BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.
To receive SMS text alerts from BioMedWire, text “Biotech” to 844-397-5787 (U.S. Mobile Phones Only)
For more information please visit https://www.biomedwire.com
Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer
BioMedWire (BMW)
San Francisco, California
www.biomedwire.com
415.949.5050 Office
Editor@BioMedWire.com
BioMedWire is part of the InvestorBrandNetwork.
